Pediatric Dermatology News

• AAD 2025 As Dermatology Continues to Grow, Pediatric Derm Numbers Lag Pediatric dermatologists love what they do but struggle to attract others to their subspecialty.
  Medscape Medical News, April 11, 2025
• New Scoring System May Streamline Food Allergy Diagnosis The NAPFA score may predict which children have a food allergy, even without allergy test results.
  Medscape Medical News, April 09, 2025
• Infections Higher With JAK Inhibitors in Eczema Study A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.
  Medscape Medical News, April 09, 2025
• Early-Onset Atopic Dermatitis Raises Uveitis Risk in Kids A cohort study finds children with early-onset atopic dermatitis to be at increased risk for uveitis, highlighting a need for ophthalmologic monitoring in youth.
  Medscape Medical News, April 04, 2025
• Ruxolitinib Shows Consistent Results Across Vitiligo Groups Ruxolitinib cream is effective and safe for treating vitiligo across different subgroups of patients, according to phase 3 studies.
  Medscape News UK, April 03, 2025
• Young Vitiligo Patients Face Hurdles to UVB Therapy A patient survey highlights significant barriers to narrowband UVB phototherapy among children with vitiligo, including limited availability and insurance challenges.
  Medscape Medical News, March 31, 2025
• Isotretinoin: Risks Beyond Depression, Suicidality Evaluated The study evaluates 20 years of the US Food and Drug Administration (FDA) Adverse Event Reporting System data.
  Medscape Medical News, March 24, 2025
• AAD 2025 Upadacitinib Dosing Increases or Decreases Found Safe in AD A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient response without serious adverse effects.
  Medscape Medical News, March 20, 2025
• Real-World Study Reveals Early Success of Upadacitinib in AD Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.
  Medscape News UK, March 20, 2025
• FDA Confirms Low Benzene Levels in Most BPO Products Tested Certain manufacturers, however, have voluntarily recalled products in the wake of FDA testing.
  Medscape Medical News, March 18, 2025
• AAD 2025 Novel Therapy Shown Effective for Atopic Dermatitis A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat immune-mediated diseases.
  Medscape Medical News, March 18, 2025
• Remote Infections Raise Risk for Surgical Site Infection Ongoing remote infections nearly double the risk for surgical site infections in intracranial neurosurgery procedures.
  Medscape News UK, March 17, 2025
• Upadacitinib Shows Efficacy in Refractory Crohn's Disease Upadacitinib induction therapy provides steroid-free clinical remission in over 50% of patients with Crohn's disease who do not respond to conventional treatment and has an acceptable safety profile.
  Medscape News UK, March 12, 2025
• AAD 2025 Delgocitinib Cream Produces Robust Response to Eczema Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped treatment stayed clear or nearly clear for 8 weeks.
  Medscape Medical News, March 09, 2025
• AAD 2025 Potentially Harmful Cosmetics Peddled to Young Girls A pediatric dermatologist calls out cosmetics retailers for aggressive marketing of products that may harm the skin of preteens and younger girls.
  Medscape Medical News, March 09, 2025
• Poor Air Quality Linked to AD Risk in Offspring Prenatal exposure to fine particulate matter (PM2.5) at levels above 65 µg/m³ was associated with a sharp rise in atopic dermatitis (AD) in a birth cohort study.
  Medscape Medical News, March 09, 2025
• Can Smokers Safely Use Upadacitinib for Atopic Dermatitis? Upadacitinib is potentially safe and effective for patients with moderate to severe atopic dermatitis, irrespective of smoking status.
  Medscape News UK, March 06, 2025
• At-Home LED Devices Reduce Acne Lesions in Meta-Analysis A systematic review finds that red and blue light-emitting diode (LED) devices significantly reduce acne lesions with minimal side effects.
  Medscape Medical News, March 05, 2025
• FDA Reviewing Roflumilast for Atopic Dermatitis in Toddlers Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years.
  Medscape Medical News, February 27, 2025
• Study Finds No Vision Issues in Children With Vitiligo Children with vitiligo do not have a higher risk for visual acuity deficits than healthy peers, a study suggests.
  Medscape Medical News, February 25, 2025